CA2808688C - Multiplex measure of isotype antigen response - Google Patents
Multiplex measure of isotype antigen response Download PDFInfo
- Publication number
- CA2808688C CA2808688C CA2808688A CA2808688A CA2808688C CA 2808688 C CA2808688 C CA 2808688C CA 2808688 A CA2808688 A CA 2808688A CA 2808688 A CA2808688 A CA 2808688A CA 2808688 C CA2808688 C CA 2808688C
- Authority
- CA
- Canada
- Prior art keywords
- target analyte
- calibration
- spots
- antibodies
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/62—Insulins
Abstract
The application discloses methods for simultaneous detection and quantifying multiple target analytes, including immunoglobulin isotypes and sub-classes, single and multiple protein antibodies within a test sample contained in a single reaction vessel. The method uses reaction wells as on a multi-well plate, each single well comprising microarrays of: (a) calibration spots, each having a predetermined quantity of a target analyte; and (b) capture spots, each having multiple agent antibodies, including isotypes and subclasses that specifically bind the target analytes. The captured analytes and the calibration spots are detected with fluorescently labeled antibodies specific for each different target analyte. Calibration spots generate calibration curves for quantitative determinations of different target analytes. The application also discloses methods for detecting and quantifying biomarkers, therapeutic proteins and patient derived antibodies; the use of secondary reagents to determine immunoglobulin classes Ig G, A, M, E and sub- classes including IgG1, IgG2, IgG3, IgG4 and IgA. The intensity of each fluorescent signal allows measurement of a specific immune response to a therapeutic protein and associated analytes; interrogates neutralizing effects of patient antibodies on therapeutic proteins e.g. insulin therapy.
Description
MULTIPLEX MEASURE OF ISOTYPE ANTIGEN RESPONSE
FIELD OF INVENTION
The present invention relates to immunogenicity testing of therapeutic biologicals with simultaneous quantification of isotype immunoglobulin classes Ig G, A, M, E, D
and sub-classes including IgGl, IgG2, IgG3, IgG4, IgA 1 and IgA2 within a single containment vessel. The invention relates to microarray methods for the simultaneous detection and quantification of multiple analytes in a single sample. Analytical components may include subunits of therapeutic proteins, including antibody fragments or fusion partners, metabolic products, peptide components, formulation components, bio-similars or potential cross reacting entities.
BACKGROUND
Current immunoassay methods detect one target per detection test cycle within a single reaction well. It is common for several antigenic substances or bio-markers to be associated with detection and diagnosis for any pathological or physiological disorder.
To confirm the presence of multiple markers, each marker within a test sample often requires a separate and different immunoassay to confirm the presence of each target analyte to be detected. This often requires a multitude of tests and samples, increases delay in time to treatment, costs and possibility of analytical error. Current immunoassay methods do not detect antibodies that are of multiple isotypes and subclasses in the same test well/cycle.
Enzyme Linked Immunosorbent Assay (ELISA) was developed by Engvall et al., Immunochem. 8: 871 (1971) and further refined by Ljunggren et al. J. Immunol.
Meth.
88: 104 (1987) and Kemeny et al., Immunol. Today 7: 67 (1986). ELISA and its applications are well known in the art.
A single ELISA functions to detect a single analyte or antibody using an enzyme-labelled antibody and a chromogenic substrate. To detect more than one analyte in a sample, a separate ELISA is performed to independently detect each analyte.
For
FIELD OF INVENTION
The present invention relates to immunogenicity testing of therapeutic biologicals with simultaneous quantification of isotype immunoglobulin classes Ig G, A, M, E, D
and sub-classes including IgGl, IgG2, IgG3, IgG4, IgA 1 and IgA2 within a single containment vessel. The invention relates to microarray methods for the simultaneous detection and quantification of multiple analytes in a single sample. Analytical components may include subunits of therapeutic proteins, including antibody fragments or fusion partners, metabolic products, peptide components, formulation components, bio-similars or potential cross reacting entities.
BACKGROUND
Current immunoassay methods detect one target per detection test cycle within a single reaction well. It is common for several antigenic substances or bio-markers to be associated with detection and diagnosis for any pathological or physiological disorder.
To confirm the presence of multiple markers, each marker within a test sample often requires a separate and different immunoassay to confirm the presence of each target analyte to be detected. This often requires a multitude of tests and samples, increases delay in time to treatment, costs and possibility of analytical error. Current immunoassay methods do not detect antibodies that are of multiple isotypes and subclasses in the same test well/cycle.
Enzyme Linked Immunosorbent Assay (ELISA) was developed by Engvall et al., Immunochem. 8: 871 (1971) and further refined by Ljunggren et al. J. Immunol.
Meth.
88: 104 (1987) and Kemeny et al., Immunol. Today 7: 67 (1986). ELISA and its applications are well known in the art.
A single ELISA functions to detect a single analyte or antibody using an enzyme-labelled antibody and a chromogenic substrate. To detect more than one analyte in a sample, a separate ELISA is performed to independently detect each analyte.
For
- 2 -example, to detect two analytes, two separate ELISA plates or two sets of wells are needed, i.e. a plate or set of wells for each analyte. Prior art chromogenic-based ELISAs detect only one analyte at a time. This is a major limitation for detecting diseases with more than one marker or transgenic organisms which express more than one transgenic product.
Macri, J. N., et al., Ann Clin Biochem 29: 390-396 (1992) describe an indirect assay wherein antibodies (Reagent-1) are reacted first with the analyte and then second labelled anti-antibodies (Reagent-2) are reacted with the antibodies of Reagent 1. The result is a need for two separate washing steps which defeats the purpose of the direct assay.
US2007141656 to Mapes et al. measures the ratio of self-antigen and auto-antibody by comparing to a bead set with monoclonal antibody specific for the self-antigen and a bead set with the self antigen. This method allows at least one analyte to react with a corresponding reactant, i.e. one analyte is a self-antigen and the reactants are auto-antibodies to the self antigen.
Another method for detecting multiple analytes is disclosed in US2005118574 to Chandler et at which makes use of flow cytometric measurement to classify, in real time, sequential automated detection and interpretation of multiple biomolecules or DNA
sequences, each biomolecule having to be separated and independently bound to a specific substrate particle, each particle being specific for separating and concentrating only a single species of analyte. This concentration of analyte is detected when the substrate particle is laser illuminated, as the particles flow, in single file, past the illuminating laser beam.
W00113120 to Chandler and Chandler determines the concentration of several different analytes in a single sample. It is necessary only that there is a unique subpopulation of microparticles for each sample / analyte combination using the flow cytometer. These bead based systems' capability is limited to each microparticle i.e. bead being suspended in a volume of test fluid that contains the analyte to be detected as a separate entity which needs to bind freely and specifically onto the surface of the test bead. Each bead effectively provides a requisite detection signal for only a specific
Macri, J. N., et al., Ann Clin Biochem 29: 390-396 (1992) describe an indirect assay wherein antibodies (Reagent-1) are reacted first with the analyte and then second labelled anti-antibodies (Reagent-2) are reacted with the antibodies of Reagent 1. The result is a need for two separate washing steps which defeats the purpose of the direct assay.
US2007141656 to Mapes et al. measures the ratio of self-antigen and auto-antibody by comparing to a bead set with monoclonal antibody specific for the self-antigen and a bead set with the self antigen. This method allows at least one analyte to react with a corresponding reactant, i.e. one analyte is a self-antigen and the reactants are auto-antibodies to the self antigen.
Another method for detecting multiple analytes is disclosed in US2005118574 to Chandler et at which makes use of flow cytometric measurement to classify, in real time, sequential automated detection and interpretation of multiple biomolecules or DNA
sequences, each biomolecule having to be separated and independently bound to a specific substrate particle, each particle being specific for separating and concentrating only a single species of analyte. This concentration of analyte is detected when the substrate particle is laser illuminated, as the particles flow, in single file, past the illuminating laser beam.
W00113120 to Chandler and Chandler determines the concentration of several different analytes in a single sample. It is necessary only that there is a unique subpopulation of microparticles for each sample / analyte combination using the flow cytometer. These bead based systems' capability is limited to each microparticle i.e. bead being suspended in a volume of test fluid that contains the analyte to be detected as a separate entity which needs to bind freely and specifically onto the surface of the test bead. Each bead effectively provides a requisite detection signal for only a specific
- 3 -analyte entity. Multiple, different entity binding events onto a single microparticle are not well distinguished or quantified using flow cytometry being restricted to multiple events of the same antibody isotype/subclass.
Simultaneous detection of more than one analyte, i.e. multiplex detection for simultaneous measurement of proteins has been described by Haab et al., "Protein micro-arrays for highly parallel detection and quantization of specific proteins and antibodies in complex solutions," Genome Biology 2(2): 0004.1-0004.13,( 2001), which is incorporated herein by reference. Mixtures of different antibodies and antigens were prepared and labelled with a red fluorescence dye and then mixed with a green fluorescence reference mixture containing the same antibodies and antigens.
The observed variation between the red to green ratio was used to reflect the variation in the concentration of the corresponding binding partner in the mixes. This method is not suitable for quantitative results.
Mezzasoma et al. (Clinical Chemistry 48, 1, 121-130 (2002) published a micro-array format method to detect analytes bound to the same capture spot in two separate assays, specifically different auto-antibodies reactive to the same antigen.
The results revealed that when incubating the captured analytes with one reporter (for example that to detect immunoglobulin IgG), the corresponding analyte is detected. When incubating the captured analytes with the second reporter in an assay using a separate microairay solid-state substrate (for example to detect IgM), a second analyte (IgM) is detected.
W00250537 to Damaj and Al-assaad discloses a method to detect up to three immobilized concomitant target antigens, bound to requisite antibodies first coated as a mixture onto a solid substrate. A wash step occurs before the first marker is detected. The presence of the first marker may be detected by adding a first specific substrate. The reaction well is read and a color change is detectable with light microscopy.
Another wash step occurs before the second marker is detected. The presence of the second marker may be detected by adding a second substrate, specific for the second enzyme, to the reaction well. After sufficient incubation, the reaction well may be assayed for a color change. Similarly, a wash step may occur before the third marker is detected.
Simultaneous detection of more than one analyte, i.e. multiplex detection for simultaneous measurement of proteins has been described by Haab et al., "Protein micro-arrays for highly parallel detection and quantization of specific proteins and antibodies in complex solutions," Genome Biology 2(2): 0004.1-0004.13,( 2001), which is incorporated herein by reference. Mixtures of different antibodies and antigens were prepared and labelled with a red fluorescence dye and then mixed with a green fluorescence reference mixture containing the same antibodies and antigens.
The observed variation between the red to green ratio was used to reflect the variation in the concentration of the corresponding binding partner in the mixes. This method is not suitable for quantitative results.
Mezzasoma et al. (Clinical Chemistry 48, 1, 121-130 (2002) published a micro-array format method to detect analytes bound to the same capture spot in two separate assays, specifically different auto-antibodies reactive to the same antigen.
The results revealed that when incubating the captured analytes with one reporter (for example that to detect immunoglobulin IgG), the corresponding analyte is detected. When incubating the captured analytes with the second reporter in an assay using a separate microairay solid-state substrate (for example to detect IgM), a second analyte (IgM) is detected.
W00250537 to Damaj and Al-assaad discloses a method to detect up to three immobilized concomitant target antigens, bound to requisite antibodies first coated as a mixture onto a solid substrate. A wash step occurs before the first marker is detected. The presence of the first marker may be detected by adding a first specific substrate. The reaction well is read and a color change is detectable with light microscopy.
Another wash step occurs before the second marker is detected. The presence of the second marker may be detected by adding a second substrate, specific for the second enzyme, to the reaction well. After sufficient incubation, the reaction well may be assayed for a color change. Similarly, a wash step may occur before the third marker is detected.
- 4 -The presence of the third marker may be detected by adding a third substrate, specific for the third enzyme, to the reaction well. After sufficient incubation, the reaction well may be assayed for a color change. Although more than one analyte may be detected in a single reaction or test well, each reaction is processed on an individual basis.
W02005017485 to Geister et al. describes a method to sequentially determine at least two different antigens in a single assay by two different enzymatic reactions of at least two enzyme labelled conjugates with two different chromogenic substrates for the enzymes in the assay (ELISA), which comprises (a) providing a first antibody specific for a first analyte and a second antibody specific for a second analyte immobilized on a solid support; (b) contacting the antibodies immobilized on the solid support with a liquid sample suspected of containing one or both of the antigens for a time sufficient for the antibodies to bind the antigens; (c) removing the solid support from the liquid sample and washing the solid support to remove unbound material; (d) contacting the solid support to a solution comprising a third antibody specific for the first antigen and a fourth antibody specific for the second antigen wherein the third antibody is conjugated to a first enzyme label and the fourth antibody is conjugated to a second enzyme label for a time sufficient for the third and fourth antibodies to bind the analytes bound by the first and second antibodies; (e) removing the solid support from the solution and washing the solid support to remove unbound antibodies; (f) adding a first chromogenic substrate for the first enzyme label wherein conversion of the first chromogenic substrate to a detectable color by the first enzyme label indicates that the sample contains the first analyte; (g) removing the first chromogenic substrate; and (h) adding a second chromogenic substrate for the second enzyme label wherein conversion of the second chromogenic substrate to a detectable color by the second enzyme label indicates that the sample contains the second analyte.
U.S. Patent 7,022,479, 2006 to Wagner, entitled "Sensitive, multiplexed diagnostic assays for protein analysis", is a method for detecting multiple different compounds in a sample, the method involving: (a) contacting the sample with a mixture of binding reagents, the binding reagents being nucleic acid-protein fusions, each having (i) a protein portion which is known to specifically bind to one of the compounds and (ii) a nucleic acid portion which includes a unique identification tag and which in one embodiment, encodes the protein; (b) allowing the protein portions of the binding
W02005017485 to Geister et al. describes a method to sequentially determine at least two different antigens in a single assay by two different enzymatic reactions of at least two enzyme labelled conjugates with two different chromogenic substrates for the enzymes in the assay (ELISA), which comprises (a) providing a first antibody specific for a first analyte and a second antibody specific for a second analyte immobilized on a solid support; (b) contacting the antibodies immobilized on the solid support with a liquid sample suspected of containing one or both of the antigens for a time sufficient for the antibodies to bind the antigens; (c) removing the solid support from the liquid sample and washing the solid support to remove unbound material; (d) contacting the solid support to a solution comprising a third antibody specific for the first antigen and a fourth antibody specific for the second antigen wherein the third antibody is conjugated to a first enzyme label and the fourth antibody is conjugated to a second enzyme label for a time sufficient for the third and fourth antibodies to bind the analytes bound by the first and second antibodies; (e) removing the solid support from the solution and washing the solid support to remove unbound antibodies; (f) adding a first chromogenic substrate for the first enzyme label wherein conversion of the first chromogenic substrate to a detectable color by the first enzyme label indicates that the sample contains the first analyte; (g) removing the first chromogenic substrate; and (h) adding a second chromogenic substrate for the second enzyme label wherein conversion of the second chromogenic substrate to a detectable color by the second enzyme label indicates that the sample contains the second analyte.
U.S. Patent 7,022,479, 2006 to Wagner, entitled "Sensitive, multiplexed diagnostic assays for protein analysis", is a method for detecting multiple different compounds in a sample, the method involving: (a) contacting the sample with a mixture of binding reagents, the binding reagents being nucleic acid-protein fusions, each having (i) a protein portion which is known to specifically bind to one of the compounds and (ii) a nucleic acid portion which includes a unique identification tag and which in one embodiment, encodes the protein; (b) allowing the protein portions of the binding
- 5 -reagents and the compounds to form complexes; (e) capturing the binding reagent-compound complexes; (d) amplifying the unique identification tags of the nucleic acid portions of the complex binding reagents; and (e) detecting the unique identification tag of each of the amplified nucleic acids, thereby detecting the corresponding compounds in the sample.
While methods for sequentially detecting and quantifying multiple analytes limited to capturing isotype and subclass for a single analyte are known, these methods require the use of separate assaying steps for each of the analytes of interest and as such, can be time consuming and costly, especially in the context of a clinical setting. There is a need for a method of sequentially detecting and quantifying multiple antibody isotypes and subclasses from a single sample using a single reaction vessel.
SUMMARY OF INVENTION
The present invention provides a fast and cost effective method for simultaneous detection and quantifying of multiple analytes in a test sample using a single reaction vessel. The method disclosed herein allows for the simultaneous detection of multiple analytes without the need for separate assays or reaction steps for each target analyte.
In one aspect, the present invention provides a method for simultaneously detecting and quantifying two or more target analytes in a test sample comprising two or more target analytes:
a) providing a reaction vessel having a microarray printed thereon, said microarray comprising:
i) a first calibration matrix comprising a plurality of the first calibration spots, each calibration spot comprising a predetermined amount of a first target analyte, the first target analyte being an antibody isotype or an antibody sub-class, ii) a second calibration matrix comprising a plurality of the second calibration spots, each calibration spot comprising a predetermined amount of a
While methods for sequentially detecting and quantifying multiple analytes limited to capturing isotype and subclass for a single analyte are known, these methods require the use of separate assaying steps for each of the analytes of interest and as such, can be time consuming and costly, especially in the context of a clinical setting. There is a need for a method of sequentially detecting and quantifying multiple antibody isotypes and subclasses from a single sample using a single reaction vessel.
SUMMARY OF INVENTION
The present invention provides a fast and cost effective method for simultaneous detection and quantifying of multiple analytes in a test sample using a single reaction vessel. The method disclosed herein allows for the simultaneous detection of multiple analytes without the need for separate assays or reaction steps for each target analyte.
In one aspect, the present invention provides a method for simultaneously detecting and quantifying two or more target analytes in a test sample comprising two or more target analytes:
a) providing a reaction vessel having a microarray printed thereon, said microarray comprising:
i) a first calibration matrix comprising a plurality of the first calibration spots, each calibration spot comprising a predetermined amount of a first target analyte, the first target analyte being an antibody isotype or an antibody sub-class, ii) a second calibration matrix comprising a plurality of the second calibration spots, each calibration spot comprising a predetermined amount of a
- 6 -second target analyte, the second target analyte being an antibody isotype or antibody sub-class, iii) a first capture matrix comprising a plurality of first capture spots, each of said first capture spots comprising a predetermined amount of a first agent which selectively binds to the target analytes, and iv) a second capture matrix comprising a plurality of second capture spots, each of said second capture spots comprising a predetermined amount of a second agent which selectively binds to the target analytes;
b) adding a predetermined volume of the test sample to the microarray;
c) simultaneously applying at least two fluorescently labelled antibodies into the same well, each of the at least two fluorescently labelled antibodies being specific for one of the target analytes for selectively binding to one of the target analytes for individual identification and quantification of said target analytes, each of said fluorescently labelled antibodies comprising a different fluorescent dye having emission and excitation spectra which do not overlap with each other;
d) measuring a signal intensity value for each of the analytes within each microarray spot;
e) generating calibration curves by fitting a curve to the measured signal intensity values for each analyte contained in each of the calibration spots versus a known concentration of the first target analyte and the second target analyte; and 0 determining the concentration for the first target analyte and the second target analytes using the generated calibration curves.
In a further embodiment of the present invention, the reaction vessel is a well of a multi-well plate where the well has the microarray printed therein.
In a further embodiment of the present invention, the test sample is a biological sample.
b) adding a predetermined volume of the test sample to the microarray;
c) simultaneously applying at least two fluorescently labelled antibodies into the same well, each of the at least two fluorescently labelled antibodies being specific for one of the target analytes for selectively binding to one of the target analytes for individual identification and quantification of said target analytes, each of said fluorescently labelled antibodies comprising a different fluorescent dye having emission and excitation spectra which do not overlap with each other;
d) measuring a signal intensity value for each of the analytes within each microarray spot;
e) generating calibration curves by fitting a curve to the measured signal intensity values for each analyte contained in each of the calibration spots versus a known concentration of the first target analyte and the second target analyte; and 0 determining the concentration for the first target analyte and the second target analytes using the generated calibration curves.
In a further embodiment of the present invention, the reaction vessel is a well of a multi-well plate where the well has the microarray printed therein.
In a further embodiment of the present invention, the test sample is a biological sample.
- 7 -In another aspect, the present invention provides a method for detecting and quantifying biomarkers diagnostic for immunogenicity testing of a therapeutic protein e.g.
insulin, comprising the following steps:
a) providing an assay device having a microarray printed thereon, said microarray comprising:
i) a plurality of calibration matrices, each comprising a plurality of calibration spots, each calibration spot comprising a predetermined amount of a target analyte being an antibody selected from the group consisting of anti-insulin peptide human immunoglobulin classes Ig G, A, M, E and sub-classes including anti-insulin human immunoglobulin peptide sub-classes IgGl, Ig02, IgG3, IgG4 and IgA.
ii) an analyte capture matrix comprising a plurality of capture spots, each capture spot comprising a predetermined amount of an agent which selectively binds to the target analytes, b) applying a predetermined volume of a serum sample to the assay device;
c) applying a plurality of different fluorescently labelled antibodies which selectively bind to human immunoglobulin classes Ig G, A, M, E, D and sub-classes including IgG 1 , IgG2, IgG3, IgG4 and IgA 1 , IgA2 respectively, the fluorescently labelled antibodies including a first fluorescently labelled anti-antibody which specifically binds to IgA antibodies, a second fluorescently labelled anti-antibody which selectively binds to IgG antibodies, a third fluorescently labelled anti-antibody which selectively binds to IgM antibodies, a fourth fluorescently labelled anti-antibody which selectively binds to IgE antibodies, a fifth fluorescently labelled anti-antibody which selectively binds to IgD antibodies, a sixth fluorescently labelled anti-antibody which selectively binds to sub-class IgG1, a seventh fluorescently labelled anti-antibody which selectively binds to sub-class IgG2, an eighth fluorescently labelled anti-antibody which selectively binds to sub-class IgG3, a ninth fluorescently labelled an anti-antibody which selectively binds to sub-class IgG4,wherein said first, second, third fourth, fifth, sixth, seventh and eighth fluorescently labelled antibodies each comprise a different fluorescent dye having emission and excitation spectra which do not overlap with each other;
insulin, comprising the following steps:
a) providing an assay device having a microarray printed thereon, said microarray comprising:
i) a plurality of calibration matrices, each comprising a plurality of calibration spots, each calibration spot comprising a predetermined amount of a target analyte being an antibody selected from the group consisting of anti-insulin peptide human immunoglobulin classes Ig G, A, M, E and sub-classes including anti-insulin human immunoglobulin peptide sub-classes IgGl, Ig02, IgG3, IgG4 and IgA.
ii) an analyte capture matrix comprising a plurality of capture spots, each capture spot comprising a predetermined amount of an agent which selectively binds to the target analytes, b) applying a predetermined volume of a serum sample to the assay device;
c) applying a plurality of different fluorescently labelled antibodies which selectively bind to human immunoglobulin classes Ig G, A, M, E, D and sub-classes including IgG 1 , IgG2, IgG3, IgG4 and IgA 1 , IgA2 respectively, the fluorescently labelled antibodies including a first fluorescently labelled anti-antibody which specifically binds to IgA antibodies, a second fluorescently labelled anti-antibody which selectively binds to IgG antibodies, a third fluorescently labelled anti-antibody which selectively binds to IgM antibodies, a fourth fluorescently labelled anti-antibody which selectively binds to IgE antibodies, a fifth fluorescently labelled anti-antibody which selectively binds to IgD antibodies, a sixth fluorescently labelled anti-antibody which selectively binds to sub-class IgG1, a seventh fluorescently labelled anti-antibody which selectively binds to sub-class IgG2, an eighth fluorescently labelled anti-antibody which selectively binds to sub-class IgG3, a ninth fluorescently labelled an anti-antibody which selectively binds to sub-class IgG4,wherein said first, second, third fourth, fifth, sixth, seventh and eighth fluorescently labelled antibodies each comprise a different fluorescent dye having emission and excitation spectra which do not overlap with each other;
- 8 -d) measuring a signal intensity value for each immunoglobulin contained within each spot forming the microarray printed in each well of the assay device;
e) generating calibration curves by fitting a curve to the measured signal intensity values for the each of the calibration spots versus the known concentration of the human IgA, IgG, IgE, IgM, IgD and subclass antibodies; and 0 determining the concentration for each of captured anti-insulin human isotype class and subclass immunoglobulins.
In another aspect, the present invention provides a method for diagnosing multiplex immunogenicity, antibody and insulin factor immunogenicity in a subject, comprising:
a) measuring the concentration levels of class and subclass anti-insulin IgA, anti-insulin IgG, anti-insulin IgM, anti-insulin IgE; and b) comparing the measured concentration levels of anti-insulin IgA, anti-insulin -IgG, anti-insulin IgM, anti-insulin IgE, anti-insulin peptide immunoglobulins IgM with index normal levels of anti-insulin immunoglobulins and anti-insulin peptide immunoglobulins wherein measured concentrations levels which exceed index normal levels is diagnostic for insulin immunogenicity.
In an embodiment of the present invention, the detection and quantification of predominantly anti-insulin IgM and anti-insulin peptide-IgM antibodies is diagnostic for an early stage of insulin immunogenicity.
In a further embodiment of the present invention, the detection and quantification of anti-insulin IgA and anti-insulin peptide-IgA antibodies is diagnostic for a transitional stage of insulin immunogenicity.
In a further embodiment of the present invention, the detection and quantification of anti-insulin IgG, anti-insulin peptide-IgG antibodies as well as their subclasses is diagnostic for a late stage of insulin immunogenicity.
e) generating calibration curves by fitting a curve to the measured signal intensity values for the each of the calibration spots versus the known concentration of the human IgA, IgG, IgE, IgM, IgD and subclass antibodies; and 0 determining the concentration for each of captured anti-insulin human isotype class and subclass immunoglobulins.
In another aspect, the present invention provides a method for diagnosing multiplex immunogenicity, antibody and insulin factor immunogenicity in a subject, comprising:
a) measuring the concentration levels of class and subclass anti-insulin IgA, anti-insulin IgG, anti-insulin IgM, anti-insulin IgE; and b) comparing the measured concentration levels of anti-insulin IgA, anti-insulin -IgG, anti-insulin IgM, anti-insulin IgE, anti-insulin peptide immunoglobulins IgM with index normal levels of anti-insulin immunoglobulins and anti-insulin peptide immunoglobulins wherein measured concentrations levels which exceed index normal levels is diagnostic for insulin immunogenicity.
In an embodiment of the present invention, the detection and quantification of predominantly anti-insulin IgM and anti-insulin peptide-IgM antibodies is diagnostic for an early stage of insulin immunogenicity.
In a further embodiment of the present invention, the detection and quantification of anti-insulin IgA and anti-insulin peptide-IgA antibodies is diagnostic for a transitional stage of insulin immunogenicity.
In a further embodiment of the present invention, the detection and quantification of anti-insulin IgG, anti-insulin peptide-IgG antibodies as well as their subclasses is diagnostic for a late stage of insulin immunogenicity.
- 9 -In another aspect, the present invention provides a method for monitoring reactions to immune stimuli by multiplex immuno testing, monitoring development of neutralizing antibodies, including for example, specific insulin immunogenicity in a subject exposed to various insulin drug immune stimuli, using the method disclosed herein, a plurality of times in the course of treatments.
BRIEF DESCRIPTION OF THE DRAWINGS
Preferred embodiments of the invention will now be described, by way of example, with reference to the accompanying drawings, in which:
Figure 1 is a schematic illustration of the multiplex analyte detection method of the present invention;
Figure 2 is a schematic illustration of the multiplex analyte immunogenicity detection content per spot, in a single well, including IgG, IgA, IgM, IgE and subclasses for method of the disclosed invention, defined as Ig_plex.
Figure 3 is a schematic illustration of a microarray printed on an assay device of the present invention;
Figure 4 illustrates typical 4 level multiplex microarray spots contained in a single well of an assay device of the present invention; and Figure 5 is a plot to illustrate composite fluorescent intensity detection for six fluorophores at non-interfering wavelengths, at 457nm (nanometers), 488 nm, 575 urn, 615nm, 667 nm and 767 nm of the present invention.
DESCRIPTION
The present invention provides a method for the detection and quantification of multiple target analytes contained within each test spot or arrays of spots, of a test or test samples, within a single reaction well, per test cycle. The method disclosed herein
BRIEF DESCRIPTION OF THE DRAWINGS
Preferred embodiments of the invention will now be described, by way of example, with reference to the accompanying drawings, in which:
Figure 1 is a schematic illustration of the multiplex analyte detection method of the present invention;
Figure 2 is a schematic illustration of the multiplex analyte immunogenicity detection content per spot, in a single well, including IgG, IgA, IgM, IgE and subclasses for method of the disclosed invention, defined as Ig_plex.
Figure 3 is a schematic illustration of a microarray printed on an assay device of the present invention;
Figure 4 illustrates typical 4 level multiplex microarray spots contained in a single well of an assay device of the present invention; and Figure 5 is a plot to illustrate composite fluorescent intensity detection for six fluorophores at non-interfering wavelengths, at 457nm (nanometers), 488 nm, 575 urn, 615nm, 667 nm and 767 nm of the present invention.
DESCRIPTION
The present invention provides a method for the detection and quantification of multiple target analytes contained within each test spot or arrays of spots, of a test or test samples, within a single reaction well, per test cycle. The method disclosed herein
- 10 -provides for the simultaneous incubation of an assay device with two or more fluorescently labelled reporters in the same detection mixture as shown in Figure 2. The method disclosed herein can detect a plurality of multiplexed analytes per test spot or capture spot, using a single reaction vessel instead of separate reaction vessels to detect each analyte. The terms "test spot" and "capture spot" can be used interchangeably for the purposes of the present specification.
Figure 1 illustrates the capturing of six different antibodies which selectively bind to two different antigens. The six different antibodies fall into three different antibody classes. In this example, an IgG is included that specifically binds to antigen A while a separate IgG is included that specifically binds to antigen B. Similarly, an IgA is included that specifically binds to antigen A while a separate IgA is included that specifically binds to antigen B. Finally, an IgM is included that specifically binds to antigen A while a separate IgM is included that specifically binds to antigen B. In such embodiments, only one calibration matrix may be required for each of the three different classes of immunoglobulins.
For example, when the target analytes of interest are different classes of human antibodies e.g. hIgG, hIgA, hIgM, hIgE and their respective subclasses are directed to the same antigen (i.e. the Fc region of hIgG), the detection and quantification of each of the target antibodies requires separate assays when conventional methods are employed.
With conventional methods, one assay is performed to detect and quantify the amount of hIgG present in a test sample. A second assay must be performed to detect and quantify the amount of hIgM and more assays must be performed to detect and quantify the presence of isoform classes and subclasses. In contrast, the method of the present invention eliminates the need for multiple detection steps thus reducing costs and time.
Using the method of the present invention, target hIgG, hIgA, hIgM, hIgD and hIgE
molecules contained in a test sample can be bound to a single capture spot in an assay device. In the disclosed method, the different classes of antibodies and antibody sub-classes can be detected in a single test by using a cocktail of fluorescently labelled antibodies directed to each of the isoform class hIgG, hIgM, hIgA, hIgE and respective subclass targets. As the antibodies are labelled with different optically excited and emitted fluorescent probes, each of the targets bound to a single capture spot can be detected and quantified using an appropriate calibrator. The use of multi-channel
Figure 1 illustrates the capturing of six different antibodies which selectively bind to two different antigens. The six different antibodies fall into three different antibody classes. In this example, an IgG is included that specifically binds to antigen A while a separate IgG is included that specifically binds to antigen B. Similarly, an IgA is included that specifically binds to antigen A while a separate IgA is included that specifically binds to antigen B. Finally, an IgM is included that specifically binds to antigen A while a separate IgM is included that specifically binds to antigen B. In such embodiments, only one calibration matrix may be required for each of the three different classes of immunoglobulins.
For example, when the target analytes of interest are different classes of human antibodies e.g. hIgG, hIgA, hIgM, hIgE and their respective subclasses are directed to the same antigen (i.e. the Fc region of hIgG), the detection and quantification of each of the target antibodies requires separate assays when conventional methods are employed.
With conventional methods, one assay is performed to detect and quantify the amount of hIgG present in a test sample. A second assay must be performed to detect and quantify the amount of hIgM and more assays must be performed to detect and quantify the presence of isoform classes and subclasses. In contrast, the method of the present invention eliminates the need for multiple detection steps thus reducing costs and time.
Using the method of the present invention, target hIgG, hIgA, hIgM, hIgD and hIgE
molecules contained in a test sample can be bound to a single capture spot in an assay device. In the disclosed method, the different classes of antibodies and antibody sub-classes can be detected in a single test by using a cocktail of fluorescently labelled antibodies directed to each of the isoform class hIgG, hIgM, hIgA, hIgE and respective subclass targets. As the antibodies are labelled with different optically excited and emitted fluorescent probes, each of the targets bound to a single capture spot can be detected and quantified using an appropriate calibrator. The use of multi-channel
- 11 -detectors allows for substantially simultaneous detection of multiplex analytes in a single assay. The spot morphology and density of capture molecules is optimized so as to mitigate for steric hindrance. As shown in Figure 2, the target analytes are IgG, IgA, IgM, IgE, IgG I, IgG2, IgG3, and IgG4. Capture spots include an antigen that binds to these antibody isotypes and subclasses. Once the target analyte antibodies bind to the capture spots, fluorescently labeled anti-IgG, anti-IgA, anti-IgM, anti-IgE, anti-IgG
1, anti-IgG2, anti-IgG3, and anti-IgG4 bind to the respective target analyte antibodies so that the amount of bound IgG, IgA, IgM. IgE, IgGl, IgG2, IgG3, and IgG4 can be detected.
The methods disclosed herein employ assay devices useful for conducting immunoassays. The assay devices may be microarrays in 2 or 3-dimensional planar array format.
In one embodiment, the method may employ the use of a multi-well plate and wherein each well has a microarray printed therein. A single well is used as a reaction vessel for assaying the desired plurality of target analytes for each test sample.
The microarray may comprise a calibration matrix comprising a series of calibration spots for each target analyte and an analyte capture matrix comprising one or more of test spots or capture spots which bind the target analytes. A
representative microarray is shown in Figure 3. The microarray 1 includes capture spots 2 and calibration spots 4. In addition internal control spots 6 are included to ensure that the microarray is functioning properly.
As used herein, the term "calibration matrix" refers to a subarray of spots printed on and adhering to the reaction vessel, wherein each spot comprises a predetermined amount of a calibration standard. The term "predetermined amount" as used herein, refers to the amount of the calibration standard as calculated based on the known concentration of the spotting buffer comprising the calibration standard and the known volume of the spotting buffer printed on the reaction vessel.
The choice of the calibration standard will depend on the nature of the target analyte. In such embodiments, the microarray will comprise a separate calibration standard for each target analyte. Alternatively, the microarray may comprise a single calibration matrix having calibration spots containing each of the target analytes.
1, anti-IgG2, anti-IgG3, and anti-IgG4 bind to the respective target analyte antibodies so that the amount of bound IgG, IgA, IgM. IgE, IgGl, IgG2, IgG3, and IgG4 can be detected.
The methods disclosed herein employ assay devices useful for conducting immunoassays. The assay devices may be microarrays in 2 or 3-dimensional planar array format.
In one embodiment, the method may employ the use of a multi-well plate and wherein each well has a microarray printed therein. A single well is used as a reaction vessel for assaying the desired plurality of target analytes for each test sample.
The microarray may comprise a calibration matrix comprising a series of calibration spots for each target analyte and an analyte capture matrix comprising one or more of test spots or capture spots which bind the target analytes. A
representative microarray is shown in Figure 3. The microarray 1 includes capture spots 2 and calibration spots 4. In addition internal control spots 6 are included to ensure that the microarray is functioning properly.
As used herein, the term "calibration matrix" refers to a subarray of spots printed on and adhering to the reaction vessel, wherein each spot comprises a predetermined amount of a calibration standard. The term "predetermined amount" as used herein, refers to the amount of the calibration standard as calculated based on the known concentration of the spotting buffer comprising the calibration standard and the known volume of the spotting buffer printed on the reaction vessel.
The choice of the calibration standard will depend on the nature of the target analyte. In such embodiments, the microarray will comprise a separate calibration standard for each target analyte. Alternatively, the microarray may comprise a single calibration matrix having calibration spots containing each of the target analytes.
- 12 -In alternate embodiments, the calibration standard is a surrogate compound.
For example if the target analyte is an antibody, the surrogate compound may be another different antibody but of the same class of immunoglobulin, as shown in Figure 4. The calibration matrix may be printed on the base of the individual reaction vessel in the format of a linear, proportional dilution series. The predetermined concentrations of calibration standards are selected to include lower and upper expected detection limits to define the dynamic range. The mid-point of dynamic calibrated concentration range approximates the diagnostic critical concentration of the detection system used to read the microarray As used herein, the term "analyte capture matrix" refers to a subarray of spots comprising agents which selectively bind the target analytes. In embodiments where the target analyte is a protein, the agent may be an analyte specific antibody or fragment thereof. Conversely, in embodiments wherein the target analyte is an antibody, the agent may be an antigen specifically bound by the antibody. For example, Figure 4 illustrates the capturing of five different antibodies which selectively bind to two different antigens.
A predetermined volume of a test sample is applied to the assay device. Each of the target analytes will bind to their specific capture spot. Thus, in a single capture spot, multiple target analytes may be bound. To detect each of the target analytes, a fluorescently labelled antibody which specifically binds to the target analyte is used.
Each fluorescently labelled antibody is coupled to a unique fluorescent dye with a specific excitation and emission wavelength to obtain the desired Stokes shift and excitation and emission coefficients. The fluorescent dyes are chosen based on their respective excitation and emission spectra such that each of the labelled antibodies comprises a different fluorescent dye having emission and excitation spectra which do not overlap with each other. The fluorescently labelled antibodies can be applied to the assay device in a single step in the form of a cocktail.
A signal intensity value for each spot within the assay device is then measured as shown in Figure 5. The fluorescent signals can be read using a combination of scanner components such as light sources and filters. A signal detector can be used to read one optical channel at a time such that each spot is imaged with multiple wavelengths, each wavelength being specific for a target analyte. An optical channel is a combination of an
For example if the target analyte is an antibody, the surrogate compound may be another different antibody but of the same class of immunoglobulin, as shown in Figure 4. The calibration matrix may be printed on the base of the individual reaction vessel in the format of a linear, proportional dilution series. The predetermined concentrations of calibration standards are selected to include lower and upper expected detection limits to define the dynamic range. The mid-point of dynamic calibrated concentration range approximates the diagnostic critical concentration of the detection system used to read the microarray As used herein, the term "analyte capture matrix" refers to a subarray of spots comprising agents which selectively bind the target analytes. In embodiments where the target analyte is a protein, the agent may be an analyte specific antibody or fragment thereof. Conversely, in embodiments wherein the target analyte is an antibody, the agent may be an antigen specifically bound by the antibody. For example, Figure 4 illustrates the capturing of five different antibodies which selectively bind to two different antigens.
A predetermined volume of a test sample is applied to the assay device. Each of the target analytes will bind to their specific capture spot. Thus, in a single capture spot, multiple target analytes may be bound. To detect each of the target analytes, a fluorescently labelled antibody which specifically binds to the target analyte is used.
Each fluorescently labelled antibody is coupled to a unique fluorescent dye with a specific excitation and emission wavelength to obtain the desired Stokes shift and excitation and emission coefficients. The fluorescent dyes are chosen based on their respective excitation and emission spectra such that each of the labelled antibodies comprises a different fluorescent dye having emission and excitation spectra which do not overlap with each other. The fluorescently labelled antibodies can be applied to the assay device in a single step in the form of a cocktail.
A signal intensity value for each spot within the assay device is then measured as shown in Figure 5. The fluorescent signals can be read using a combination of scanner components such as light sources and filters. A signal detector can be used to read one optical channel at a time such that each spot is imaged with multiple wavelengths, each wavelength being specific for a target analyte. An optical channel is a combination of an
- 13 -excitation source and an excitation filter, matched for the excitation at a specific wavelength. The emission filter and emission detector pass only a signal wavelength for a specific fluorescent dye. The optical channels used for a set of detectors are selected such that they do not interfere with each other, i.e. the excitation through one channel excites only the intended dye, not any other dyes. Alternatively, a multi-channel detector can be used to detect each of the differentially labelled antibodies. The use of differential fluorescent labels allows for substantially simultaneous detection of the multiple target analytes bound to a single capture spot.
The intensity of the measured signal is directly proportional to the amount of material contained within the printed calibration spots and the amount of analyte from the test sample bound to the printed analyte capture spot. For each calibration compound, a calibration curve is generated by fitting a curve to the measured signal intensity values versus the known concentration of the calibration compound. The concentration for each target analyte in the test sample is then determined using the appropriate calibration curve and by plotting the measured signal intensity for the target analyte on the calibration curve.
The method disclosed herein can be used to detect and quantify multiple clinically relevant biomarkers in a biological sample for diagnostic or prognostic purposes. The measured concentrations for a disease related biomarker can be compared with established index normal levels for that biomarker. The measured concentrations levels which exceed index normal levels may be identified as being diagnostic of the disease.
The method disclosed herein can also be used to monitor the progress of a disease and also the effect of a treatment on the disease. Levels of a clinically relevant biomarker can be quantified using the disclosed method a plurality of times during a period of treatment.
A trending decrease in biomarker levels may be correlated with a positive and/or negative patient response to treatment.
The method disclosed herein can be used to detect and quantify biomarkers diagnostic for insulin immunogenicity. In one embodiment, the method comprises the provision of an assay device having a microarray printed thereon. The microatray may comprise: i) a calibration matrix comprising plurality of calibration spots, each calibration spot comprising a predetermined amount of one of: a human IgA antibody, a human IgG
The intensity of the measured signal is directly proportional to the amount of material contained within the printed calibration spots and the amount of analyte from the test sample bound to the printed analyte capture spot. For each calibration compound, a calibration curve is generated by fitting a curve to the measured signal intensity values versus the known concentration of the calibration compound. The concentration for each target analyte in the test sample is then determined using the appropriate calibration curve and by plotting the measured signal intensity for the target analyte on the calibration curve.
The method disclosed herein can be used to detect and quantify multiple clinically relevant biomarkers in a biological sample for diagnostic or prognostic purposes. The measured concentrations for a disease related biomarker can be compared with established index normal levels for that biomarker. The measured concentrations levels which exceed index normal levels may be identified as being diagnostic of the disease.
The method disclosed herein can also be used to monitor the progress of a disease and also the effect of a treatment on the disease. Levels of a clinically relevant biomarker can be quantified using the disclosed method a plurality of times during a period of treatment.
A trending decrease in biomarker levels may be correlated with a positive and/or negative patient response to treatment.
The method disclosed herein can be used to detect and quantify biomarkers diagnostic for insulin immunogenicity. In one embodiment, the method comprises the provision of an assay device having a microarray printed thereon. The microatray may comprise: i) a calibration matrix comprising plurality of calibration spots, each calibration spot comprising a predetermined amount of one of: a human IgA antibody, a human IgG
- 14 -antibody, a human IgM antibody, a human IgE antibody and respective subclasses; ii) a first analyte capture matrix comprising a plurality of capture spots comprising a predetermined amount of a compound, for example, insulin; and optionally iii) a second analyte capture matrix comprising a plurality of capture spots comprising a predetermined amount of anti-insulin peptide. A predetermined volume of a biological sample, preferably a serum sample, is applied to the assay device. A cocktail comprising a first fluorescently labelled reporter compound which selectively binds to IgA
antibodies, a second fluorescently labelled reporter compound which selectively binds to IgG
antibodies, a third fluorescently labelled reporter compound which selectively binds to IgM antibodies, a fourth fluorescently labelled reporter which selective binds to IgE and fluorescent labels which bind selectively to imtnunoglobulin subclasses, is then applied to the assay device. The first, second, third, fourth and selected subclass fluorescently labelled antibodies are chosen such that each of the antibodies comprises a different fluorescent dye having emission and excitation spectra which do not overlap with each other, as shown in Figure 5. A signal intensity value for each spot within the assay device is then measured using a single or multi-channel detector as discussed above.
Using the measured signal intensity values, calibration curves are then generated by fitting a curve to the measured signal intensity values for each of the calibration spots versus the concentration of the human IgA, IgG, IgM, IgE and subclass antibodies. The concentration for each of the captured insulin analytes is determined using the calibration curves.
In certain embodiments, the method disclosed herein can be used to diagnose or monitor the progress of autoimmune diseases. In other embodiments, the method disclosed herein can be used for monitoring the progress of treatment.
Example 1 ¨ Multiplex Immunoaenicitv Testinz Wherein a therapeutic protein and /or its analytical components are immobilized on a planar microarray surface analytical components may include subunits of the.
Analytical components include subunits of the therapeutic protein e.g. antibody fragments or fusion partners, metabolic products of said therapeutic protein, peptide components, formulation components, biosimilars, or potential cross reacting entities.
antibodies, a second fluorescently labelled reporter compound which selectively binds to IgG
antibodies, a third fluorescently labelled reporter compound which selectively binds to IgM antibodies, a fourth fluorescently labelled reporter which selective binds to IgE and fluorescent labels which bind selectively to imtnunoglobulin subclasses, is then applied to the assay device. The first, second, third, fourth and selected subclass fluorescently labelled antibodies are chosen such that each of the antibodies comprises a different fluorescent dye having emission and excitation spectra which do not overlap with each other, as shown in Figure 5. A signal intensity value for each spot within the assay device is then measured using a single or multi-channel detector as discussed above.
Using the measured signal intensity values, calibration curves are then generated by fitting a curve to the measured signal intensity values for each of the calibration spots versus the concentration of the human IgA, IgG, IgM, IgE and subclass antibodies. The concentration for each of the captured insulin analytes is determined using the calibration curves.
In certain embodiments, the method disclosed herein can be used to diagnose or monitor the progress of autoimmune diseases. In other embodiments, the method disclosed herein can be used for monitoring the progress of treatment.
Example 1 ¨ Multiplex Immunoaenicitv Testinz Wherein a therapeutic protein and /or its analytical components are immobilized on a planar microarray surface analytical components may include subunits of the.
Analytical components include subunits of the therapeutic protein e.g. antibody fragments or fusion partners, metabolic products of said therapeutic protein, peptide components, formulation components, biosimilars, or potential cross reacting entities.
- 15 -Samples collected from untreated and therapeutic protein treated patients are incubated with the immobilized microarray components. Samples are most likely to be serum or plasma. These samples may be pre-treated or prepared in such a way as to enrich for the availability of any antibodies which the patient may have developed in response to the therapeutic protein or prior exposure to similar entities. Following sample incubation the microarray surface is interrogated for the presence of patient derived antibodies which have been captured and bound by the immobilized analytes.
The amount of and heavy chain characteristics of the captured patient antibodies are determined by the use of specific anti-human secondary antibodies which have been conjugated to fluorescent dyes.
Secondary reagents can be included to determine the immunoglobulin class Ig G, A, M or E or the sub- classes, including IgGl, IgG2, IgG3, and IgG4. Specific dyes are conjugated to each of the secondary reagents to constitute a reporter and allow differentiation of each of the Ig classes or subclasses. A reporter aliquot is made up of a mix of conjugates as determined by the classes and subclasses that are of interest in the patient study This assay can be configured to use (i) a three color fluorescent scanner by including the same patient sample in multiple interrogated wells and adding a three color constituent reporter blend to each of the wells; or (ii) increased to multiples of up to six colors per well as determined by selecting fluorescent dyes which have separable emission peaks used in conjunction with a scanner equipped with appropriate excitation and emission filters.
The intensity of the multiple fluorescent signals when compared to standard curves intensities will allow the qualitative and quantified measurement of a specific immune response to the therapeutic protein or the protein associated analytes.
Example 2: Neutralizine Antibodies The method also interrogates neutralizing effects of a patient's antibodies, ie; their ability to directly affect the active mechanism of the therapeutic protein
The amount of and heavy chain characteristics of the captured patient antibodies are determined by the use of specific anti-human secondary antibodies which have been conjugated to fluorescent dyes.
Secondary reagents can be included to determine the immunoglobulin class Ig G, A, M or E or the sub- classes, including IgGl, IgG2, IgG3, and IgG4. Specific dyes are conjugated to each of the secondary reagents to constitute a reporter and allow differentiation of each of the Ig classes or subclasses. A reporter aliquot is made up of a mix of conjugates as determined by the classes and subclasses that are of interest in the patient study This assay can be configured to use (i) a three color fluorescent scanner by including the same patient sample in multiple interrogated wells and adding a three color constituent reporter blend to each of the wells; or (ii) increased to multiples of up to six colors per well as determined by selecting fluorescent dyes which have separable emission peaks used in conjunction with a scanner equipped with appropriate excitation and emission filters.
The intensity of the multiple fluorescent signals when compared to standard curves intensities will allow the qualitative and quantified measurement of a specific immune response to the therapeutic protein or the protein associated analytes.
Example 2: Neutralizine Antibodies The method also interrogates neutralizing effects of a patient's antibodies, ie; their ability to directly affect the active mechanism of the therapeutic protein
- 16 -In cases where the therapeutic protein is a ligand that binds to a receptor, the receptor will be immobilized on the array surface. A fluorescently labeled derivative of the therapeutic protein will be incubated with patient serum in a competitive type immunoassay. A high fluorescent signal in this case indicates an absence of neutralizing antibodies. As the titer of neutralizing antibodies increases in a sample, they will interfere with the ability of the labeled therapeutic protein to bind the receptor and thus decrease the florescent signal on the array surface.
In cases where the mechanism of the therapeutic protein is to block a ligand/receptor interaction: the receptor is immobilized on the microarray surface. A
fluorescently labeled derivative of the appropriate ligand, and the therapeutic protein is incubated with patient serum. In the absence of neutralizing antibodies the therapeutic protein will block the binding of the labeled ligand to the receptor and little or no fluorescent signal will be detected. As the titer of neutralizing antibodies increases, they will interfere with the ability of the therapeutic protein to block the ligand/receptor interaction, and the fluorescent signal will increase.
Example 3 Insulin Immunogenicity As new insulin variants are developed the need to study the range of immune responses in patients requires the ability to detect, characterize and quantitate anti-insulin antibodies.
Regardless of purity and origin, therapeutic insulins continue to be immunogenic in humans. Severe immunological complications rarely occur. Current human insulin and insulin analog therapies result in decreased anti-insulin antibodies levels.
Anti-insulin antibody development is also affected by the mode of delivery: e.g. use of subcutaneous and implantable insulin pumps or inhaled insulin. Formulation also effects immunogenic potential with regular or semilente insulins being less immunogenic than intermediate or long acting preparations. Aggregation levels also affect immunogenicity.
Anti-insulin antibodies responses consisting of Ig classes and IgG subclasses have been reported. Primarily IgG1-4 but IgA, IgM and IgE have also been reported.
IgG is implicated in the most severe cases of insulin resistance. Insulin delivered or inhaled results in a similar distribution of IgG subclasses: IgG1 >IgG4 > IgG2 and IgG3. IgG1
In cases where the mechanism of the therapeutic protein is to block a ligand/receptor interaction: the receptor is immobilized on the microarray surface. A
fluorescently labeled derivative of the appropriate ligand, and the therapeutic protein is incubated with patient serum. In the absence of neutralizing antibodies the therapeutic protein will block the binding of the labeled ligand to the receptor and little or no fluorescent signal will be detected. As the titer of neutralizing antibodies increases, they will interfere with the ability of the therapeutic protein to block the ligand/receptor interaction, and the fluorescent signal will increase.
Example 3 Insulin Immunogenicity As new insulin variants are developed the need to study the range of immune responses in patients requires the ability to detect, characterize and quantitate anti-insulin antibodies.
Regardless of purity and origin, therapeutic insulins continue to be immunogenic in humans. Severe immunological complications rarely occur. Current human insulin and insulin analog therapies result in decreased anti-insulin antibodies levels.
Anti-insulin antibody development is also affected by the mode of delivery: e.g. use of subcutaneous and implantable insulin pumps or inhaled insulin. Formulation also effects immunogenic potential with regular or semilente insulins being less immunogenic than intermediate or long acting preparations. Aggregation levels also affect immunogenicity.
Anti-insulin antibodies responses consisting of Ig classes and IgG subclasses have been reported. Primarily IgG1-4 but IgA, IgM and IgE have also been reported.
IgG is implicated in the most severe cases of insulin resistance. Insulin delivered or inhaled results in a similar distribution of IgG subclasses: IgG1 >IgG4 > IgG2 and IgG3. IgG1
- 17 -levels have been reported to decline where IgG4 rises with increased duration of insulin treatment.
The method disclosed is uniquely suited to detect and differentiate the range of anti-insulin antibodies in a single assay, as opposed to running a separate assay for each Ig class or subclass.
In this case the therapeutic insulin is printed as multiple replicate spots in each well of a 96 well functionalized glass plate. The print conditions, including buffers, concentration, and post print processes are selected to optimize eptitope presentation and assay precision. Assay controls including anti-human antibodies or other variants of insulin could be included in each of the 96 wells.
Each well is incubated with patient serum. In cases where the patient has anti-insulin antibodies they are captured by the spotted insulin. Fluorescently labeled anti-human Ig secondary reagents are used to detect the binding anti-insulin antibodies.
Secondary reagents include Ig Class specific ( IgG, IgA , IgM or IgE) or subclasss specific (IgGl, IgG2, IgG3, IgG4). A Fluorescent dye with a different emission spectrum is conjugated to each of the secondary reagents allowing the patient immune response to be characterized based on the intensity of each signal.
In the case where a commercial 3-color array scanner is used to detect the fluorescent signals, the same patient sample is interrogated in multiple wells and different aliquots of labeled reporters are used to fluorescently label each reporter in each well with a specific dye wavelength, e.g. in Well 1, IgA is labeled with dye Cy5 at 667 nm (nanometers), IgG1 with dye FITC at 488 nm and IgG3 with dye PE at 575 nm to measure the IgA, IgG1 and IgG3 in Well 1. In Well 2, IgM is labeled with Cy5 at 667 nm, IgG2 is labeled with FITC at 488 nm and IgG4 is labeled with PE to fluoresce at 575 nm to measure IgM, IgG2 and IgG4. The six immunoglobulins are measured using only three fluorescing labels.
For simultaneous detection of up to six different color fluorescent wavelengths per well, as illustrated in Figure 5, the excitation source and emission filters are coordinated with a set of dyes with compatible spectra; IGg 1 -FITC dye at 488 nm, IgG2- PE dye at 575 nm, IgG3 - Cy5 dye at 667 nm, IgG4 - Pe-Cy dye at 767 nm, IgA- Pac Blue dye at 457 run,
The method disclosed is uniquely suited to detect and differentiate the range of anti-insulin antibodies in a single assay, as opposed to running a separate assay for each Ig class or subclass.
In this case the therapeutic insulin is printed as multiple replicate spots in each well of a 96 well functionalized glass plate. The print conditions, including buffers, concentration, and post print processes are selected to optimize eptitope presentation and assay precision. Assay controls including anti-human antibodies or other variants of insulin could be included in each of the 96 wells.
Each well is incubated with patient serum. In cases where the patient has anti-insulin antibodies they are captured by the spotted insulin. Fluorescently labeled anti-human Ig secondary reagents are used to detect the binding anti-insulin antibodies.
Secondary reagents include Ig Class specific ( IgG, IgA , IgM or IgE) or subclasss specific (IgGl, IgG2, IgG3, IgG4). A Fluorescent dye with a different emission spectrum is conjugated to each of the secondary reagents allowing the patient immune response to be characterized based on the intensity of each signal.
In the case where a commercial 3-color array scanner is used to detect the fluorescent signals, the same patient sample is interrogated in multiple wells and different aliquots of labeled reporters are used to fluorescently label each reporter in each well with a specific dye wavelength, e.g. in Well 1, IgA is labeled with dye Cy5 at 667 nm (nanometers), IgG1 with dye FITC at 488 nm and IgG3 with dye PE at 575 nm to measure the IgA, IgG1 and IgG3 in Well 1. In Well 2, IgM is labeled with Cy5 at 667 nm, IgG2 is labeled with FITC at 488 nm and IgG4 is labeled with PE to fluoresce at 575 nm to measure IgM, IgG2 and IgG4. The six immunoglobulins are measured using only three fluorescing labels.
For simultaneous detection of up to six different color fluorescent wavelengths per well, as illustrated in Figure 5, the excitation source and emission filters are coordinated with a set of dyes with compatible spectra; IGg 1 -FITC dye at 488 nm, IgG2- PE dye at 575 nm, IgG3 - Cy5 dye at 667 nm, IgG4 - Pe-Cy dye at 767 nm, IgA- Pac Blue dye at 457 run,
- 18 -IgM - Alexa fluor dye at 594 615 nm. If more than six fluorescent labels are required to report and measure multiple antigens, the identified set, or compatible sets of six wavelengths are applied in each separate well. It is to be understood that more than six different color fluorescent wavelengths per well can be detected in alternate embodiments of the present invention.
Various embodiments of the present invention having been thus described in detail by way of example, it will be apparent to those skilled in the art that variations and modifications may be made without departing from the invention. The invention includes all such variations and modifications as fall within the scope of the appended claims.
Various embodiments of the present invention having been thus described in detail by way of example, it will be apparent to those skilled in the art that variations and modifications may be made without departing from the invention. The invention includes all such variations and modifications as fall within the scope of the appended claims.
Claims (3)
1. A method for simultaneously detecting and quantifying two target analytes in a test sample comprising two target analytes, contained in a single reaction vessel, comprising the following steps:
a) providing a reaction vessel having a microarray printed thereon, said microarray comprising:
i) a first calibration matrix comprising a plurality of first calibration spots, each of the first calibration spots comprising a predetermined amount of a first target analyte, the first target analyte being an antibody sub-class, the antibody sub-class being sub-class IgGl, ii) a second calibration matrix comprising a plurality of second calibration spots, each of the second calibration spots comprising a predetermined amount of a second target analyte, the second target analyte being an antibody sub-class, the antibody sub-class being sub-class IgG2, iii) a first capture matrix comprising a plurality of first capture spots, each of said first capture spots comprising a predetermined amount of a first agent which selectively binds to the first target analyte and to the second target analyte, and iv) a second capture matrix comprising a plurality of second capture spots, each of said second capture spots comprising a predetemiined amount of a second agent which selectively binds to the first target analyte and to the second target analyte, and b) adding a predetermined volume of the test sample to the microarray;
Date Recue/Date Received 2021-02-25 c) simultaneously applying a first fluorescently labelled antibody and a second fluorescently labelled antibody to the microarray, the first fluorescently labelled antibody being specific for the first target analyte for selectively binding to the first target analyte for identification and quantification of said first target analyte, the second fluorescently labelled antibody being specific for the second target analyte for selectively binding to the second target analyte for identification and quantification of said second target analyte, each of said first and second fluorescently labelled antibodies comprising a different fluorescent dye having emission and excitation spectra which do not overlap with each other;
d) measuring a signal intensity value for each fluorescently wavelength for each calibration spot and each capture spot within the microarray;
e) generating calibration curves by fitting a curve to the measured signal intensity values for each of the calibration spots versus a known concentration of the first target analyte and the second target analyte in the calibration spots; and f) determining the concentration for the first target analyte and the second target analyte bound to the capture spots using the generated calibration curves.
a) providing a reaction vessel having a microarray printed thereon, said microarray comprising:
i) a first calibration matrix comprising a plurality of first calibration spots, each of the first calibration spots comprising a predetermined amount of a first target analyte, the first target analyte being an antibody sub-class, the antibody sub-class being sub-class IgGl, ii) a second calibration matrix comprising a plurality of second calibration spots, each of the second calibration spots comprising a predetermined amount of a second target analyte, the second target analyte being an antibody sub-class, the antibody sub-class being sub-class IgG2, iii) a first capture matrix comprising a plurality of first capture spots, each of said first capture spots comprising a predetermined amount of a first agent which selectively binds to the first target analyte and to the second target analyte, and iv) a second capture matrix comprising a plurality of second capture spots, each of said second capture spots comprising a predetemiined amount of a second agent which selectively binds to the first target analyte and to the second target analyte, and b) adding a predetermined volume of the test sample to the microarray;
Date Recue/Date Received 2021-02-25 c) simultaneously applying a first fluorescently labelled antibody and a second fluorescently labelled antibody to the microarray, the first fluorescently labelled antibody being specific for the first target analyte for selectively binding to the first target analyte for identification and quantification of said first target analyte, the second fluorescently labelled antibody being specific for the second target analyte for selectively binding to the second target analyte for identification and quantification of said second target analyte, each of said first and second fluorescently labelled antibodies comprising a different fluorescent dye having emission and excitation spectra which do not overlap with each other;
d) measuring a signal intensity value for each fluorescently wavelength for each calibration spot and each capture spot within the microarray;
e) generating calibration curves by fitting a curve to the measured signal intensity values for each of the calibration spots versus a known concentration of the first target analyte and the second target analyte in the calibration spots; and f) determining the concentration for the first target analyte and the second target analyte bound to the capture spots using the generated calibration curves.
2. The method according to claim 1, wherein the reaction vessel is a well of a multi-well plate and wherein each well has the microarray printed therein.
3. The method according to claim 1, wherein the test sample is a biological sample.
Date Recue/Date Received 2021-02-25
Date Recue/Date Received 2021-02-25
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3152467A CA3152467A1 (en) | 2013-03-08 | 2013-03-08 | Multiplex measure of isotype antigen response |
| CA2808688A CA2808688C (en) | 2013-03-08 | 2013-03-08 | Multiplex measure of isotype antigen response |
| CA3152470A CA3152470A1 (en) | 2013-03-08 | 2013-03-08 | Multiplex measure of isotype antigen response |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2808688A CA2808688C (en) | 2013-03-08 | 2013-03-08 | Multiplex measure of isotype antigen response |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3152470A Division CA3152470A1 (en) | 2013-03-08 | 2013-03-08 | Multiplex measure of isotype antigen response |
| CA3152467A Division CA3152467A1 (en) | 2013-03-08 | 2013-03-08 | Multiplex measure of isotype antigen response |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2808688A1 CA2808688A1 (en) | 2014-09-08 |
| CA2808688C true CA2808688C (en) | 2022-06-07 |
Family
ID=51730167
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3152470A Pending CA3152470A1 (en) | 2013-03-08 | 2013-03-08 | Multiplex measure of isotype antigen response |
| CA2808688A Active CA2808688C (en) | 2013-03-08 | 2013-03-08 | Multiplex measure of isotype antigen response |
| CA3152467A Pending CA3152467A1 (en) | 2013-03-08 | 2013-03-08 | Multiplex measure of isotype antigen response |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3152470A Pending CA3152470A1 (en) | 2013-03-08 | 2013-03-08 | Multiplex measure of isotype antigen response |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3152467A Pending CA3152467A1 (en) | 2013-03-08 | 2013-03-08 | Multiplex measure of isotype antigen response |
Country Status (1)
| Country | Link |
|---|---|
| CA (3) | CA3152470A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105785032A (en) * | 2016-03-23 | 2016-07-20 | 广州瑞博奥生物科技有限公司 | Antibody chip kit capable of simultaneously and quantitatively detecting plurality of immunoglobulin subtypes |
-
2013
- 2013-03-08 CA CA3152470A patent/CA3152470A1/en active Pending
- 2013-03-08 CA CA2808688A patent/CA2808688C/en active Active
- 2013-03-08 CA CA3152467A patent/CA3152467A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2808688A1 (en) | 2014-09-08 |
| CA3152470A1 (en) | 2014-09-08 |
| CA3152467A1 (en) | 2014-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20110306511A1 (en) | Methods for multiplex analyte detection and quantification | |
| Rivnak et al. | A fully-automated, six-plex single molecule immunoassay for measuring cytokines in blood | |
| US7396689B2 (en) | Method of adjusting the working range of a multi-analyte assay | |
| JP6495382B2 (en) | Spatial resolution ligand-receptor binding assay | |
| US9274056B2 (en) | Use of non-chelated fluorochromes in rapid test systems | |
| US20190204310A1 (en) | Multiplex measure of isotype antigen response | |
| JP4274944B2 (en) | Particle-based ligand assay with extended dynamic range | |
| EP2639584A1 (en) | Real time diagnostic assays using an evanescence biosensor | |
| KR101718485B1 (en) | Device for Detecting Colored Reaction or Fluorescence Reaction of Immunochromatography | |
| Carl et al. | Wash-free multiplexed mix-and-read suspension array fluorescence immunoassay for anthropogenic markers in wastewater | |
| RU2698311C2 (en) | Analysis for glycated proteins | |
| JP2005510706A5 (en) | ||
| US20130165335A1 (en) | Multiplex measure of isotype antigen response | |
| US20070238140A1 (en) | Method For Multiplex Bead-Based Assays Using Chemiluminescence and Fluorescence | |
| JP2005528612A (en) | A novel method for monitoring biomolecular interactions | |
| US20230305001A1 (en) | Ultra-sensitive digital rapid chromatographic assay system and method for analytes detection | |
| US20100075864A1 (en) | Measurement of complement activation products on antigen arrays | |
| KR20160110701A (en) | Biomaterial Analysis Device Comprising Membrane Based Multiple Tube | |
| CA2808688C (en) | Multiplex measure of isotype antigen response | |
| US11668711B2 (en) | Multiplexed diagnostic assay for iron and vitamin A deficiency and methods of use thereof | |
| US20180231539A1 (en) | Device and method for detecting substances present in biological or chemical samples | |
| WO2007016665A2 (en) | Single use fluorescent assays for determination of analytes | |
| KR20150111391A (en) | Immunochromatography Analysis Device | |
| JPS6336151A (en) | Quantitative determination of fine particle by measuring fluorescent intensity | |
| JP7425138B2 (en) | Optical imaging system using side illumination for digital assays |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180306 |
|
| EEER | Examination request |
Effective date: 20180306 |